A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsd Moores Cancer Center
San Diego, California, United States
- Stanford Comprehensive Cancer Center
Stanford, California, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester
Rochester, Minnesota, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2008
- Primary completion
- 31 Oct 2009
- Completion
- 31 Oct 2009
- Last update posted
- 26 Oct 2009
- Registered enrollment
- 59
- Registry id
- NCT00631462
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.